Multi-receptor Targeting of Glioblastoma

胶质母细胞瘤的多受体靶向

基本信息

项目摘要

Treatment of glioblastoma (GBM) represents an unmet need in medicine. We have been pursuing a therapeutic approach of delivering potent targeted and specific cytotoxins using convection-enhanced delivery (CED). We and others found that patients with GBM over-express interleukin 13 receptor alpha 2 (IL-13RA2), EphA2, EphA3 and EphB2 receptors. These receptors are present in various pathophysiological compartments of GBM and all four are expressed in tumor cells of the core of tumor and in locally-infiltrating tumor cells, while EphA2 is also found in tumor neovasculature. Further, IL-13RA2, EphA2, and EphA3 are associated with, and play crucial roles in, the pathobiology of glioma stem-like cells (GSC). Finally, the EphA3 receptor can be readily detected in M2 tumor-associated macrophages (TMA). Thus, collectively, IL-13RA2, EphA2, EphA3 and EphB2 are over-expressed in principal GBM compartments shown to be involved in tumor progression and/or resistance to therapies. One of the Eph receptor ligands, ephrinA5 (eA5), binds EphA2, EphA3 and EphB2 receptors. In the current project, we will pursue the novel idea of targeting all four receptors with one pharmaceutical compound delivered using monitored and effective CED. We have already engineered an agent based on eA5 and IL-13 mutants targeting all four receptors using an IgG1 scaffold and conjugated it to a modified bacterial toxin to form QUAD 3.0-PE38QQR. The conjugate is safe and effective in GBM tumors. We will continue this exciting line of research through three Specific Aims. In Specific Aim 1, we will evaluate QUAD 3.0-PE38QQR distribution, safety and anti-tumor activity in treating canine high-grade gliomas, which represents the closest model of human disease. In Specific Aim 2, we will develop QUAD 3.0-PE38QQR for first-in-human Phase I clinical trial in patients with recurrent GBM. We will make QUAD 3.0-PE38QQR under Good Manufacturing Practices (GMP) conditions. The QUAD-CTX will undergo pre-clinical animal studies, based on pre-IND discussions with the FDA. Studies will be performed under Good Laboratory Practices (GLP) conditions in order to obtain an Investigational New Drug (IND). In the third Specific Aim, we will perform Phase I clinical trial with QUAD 3.0-PE38QQR in patients with recurrent GBM. The focus will be on obtaining optimal volume of distribution of the CED-administered drug, its safety, initial efficacy and evidence of inducing immune responses. Thus, with one therapeutic agent and improved delivery system, we will be eliminating tumor cells and abnormal cells of the tumor microenvironment promoting its growth. This approach also addresses crucial issues of inter- and intra-tumoral heterogeneity and is also expected to evoke an in situ vaccination or so called “tumor inflaming” effect. We envision that this all-out assault, termed by us “molecular resection”, will result in a more effective management of GBM.
胶质母细胞瘤(GBM)的治疗代表了医学上未满足的需求。我们一直在寻找 使用对流增强递送递送有效的靶向和特异性细胞毒素的治疗方法 (CED)。我们和其他人发现GBM患者过度表达白细胞介素13受体α 2(IL-13 RA 2), EphA 2、EphA 3和EphB 2受体。这些受体存在于不同的病理生理区室 GBM和所有四种都在肿瘤核心的肿瘤细胞和局部浸润的肿瘤细胞中表达, EphA 2也存在于肿瘤新生血管中。此外,IL-13 RA 2、EphA 2和EphA 3与以下相关,并且 在神经胶质瘤干细胞样细胞(GSC)的病理生物学中起关键作用。最后,EphA 3受体可以是 在M2肿瘤相关巨噬细胞(TMA)中容易检测到。因此,IL-13 RA 2、EphA 2、EphA 3 和EphB 2在显示参与肿瘤进展的主要GBM区室中过表达 和/或对治疗的抗性。Eph受体配体之一ephrinA 5(eA 5)结合EphA 2、EphA 3和EphA 4。 EphB 2受体。在目前的项目中,我们将追求用一种靶向所有四种受体的新想法。 使用受监控且有效的CED递送药物化合物。我们已经设计了一个 基于eA 5和IL-13突变体的试剂,使用IgG 1支架靶向所有四种受体,并将其缀合至 修饰细菌毒素以形成QUAD 3.0-PE 38 QQR。该缀合物在GBM肿瘤中是安全有效的。我们 将通过三个具体目标继续这一令人兴奋的研究路线。在具体目标1中,我们将评估 QUAD 3.0-PE 38 QQR治疗犬高级别胶质瘤的分布、安全性和抗肿瘤活性, 代表了最接近人类疾病的模型。在具体目标2中,我们将开发QUAD 3.0-PE 38 QQR, 在复发性GBM患者中进行的首次人体I期临床试验。我们将使QUAD 3.0-PE 38 QQR下 良好生产规范(GMP)条件。QUAD-CTX将进行临床前动物研究, 基于与FDA的IND前讨论。研究将按照药物非临床研究质量管理规范(GLP)进行 申请新药研究申请(IND)。在第三个具体目标中,我们将执行 QUAD 3.0-PE 38 QQR在复发性GBM患者中的I期临床试验。重点将是获得 CED给药药物的最佳分布容积、其安全性、初始疗效和诱导证据 免疫反应。因此,用一种治疗剂和改进的递送系统,我们将 清除肿瘤细胞和促进其生长的肿瘤微环境的异常细胞。这 这种方法还解决了肿瘤间和肿瘤内异质性的关键问题, 原位接种或所谓的“肿瘤发炎”效应。我们设想这场被我们称为 “分子切除”,将导致更有效的管理GBM。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Waldemar Debinski其他文献

Waldemar Debinski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Waldemar Debinski', 18)}}的其他基金

Combinatorial Immunotherapy using a Multivalent Drug Conjugate for GBM Treatment
使用多价药物偶联物进行 GBM 治疗的组合免疫疗法
  • 批准号:
    10560392
  • 财政年份:
    2022
  • 资助金额:
    $ 61.57万
  • 项目类别:
Multi-receptor Targeting of Glioblastoma
胶质母细胞瘤的多受体靶向
  • 批准号:
    10313101
  • 财政年份:
    2021
  • 资助金额:
    $ 61.57万
  • 项目类别:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
机构的子组件
  • 批准号:
    10220881
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBM
机构的子组件
  • 批准号:
    10493966
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
最大限度地提高胶质母细胞瘤的本地治疗交付机会
  • 批准号:
    9978729
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Sub-component for Institution # 16-01848 Core 1 - Administrative
机构的子组件
  • 批准号:
    10220885
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Rapid Electrical Impedance Spectroscopy for Detection of High-Frequency Irreversible Electroporation Ablation Growth in a Rodent Glioma Model
快速电阻抗光谱法检测啮齿动物神经胶质瘤模型中高频不可逆电穿孔消融生长
  • 批准号:
    10310562
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Maximizing Local Access to Therapeutic Deliveries in Glioblastoma
最大限度地提高胶质母细胞瘤的本地治疗交付机会
  • 批准号:
    10220880
  • 财政年份:
    2017
  • 资助金额:
    $ 61.57万
  • 项目类别:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
多形性胶质母细胞瘤的分子组合治疗
  • 批准号:
    8010645
  • 财政年份:
    2010
  • 资助金额:
    $ 61.57万
  • 项目类别:
Molecular Combinatorial Therapy of Glioblastoma Multiforme
多形性胶质母细胞瘤的分子组合治疗
  • 批准号:
    8385587
  • 财政年份:
    2010
  • 资助金额:
    $ 61.57万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.57万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了